RxDoctor Payments Data

Richard Miller, MD

Ophthalmology · Rockford, ILNPI 1134127871

Payments from drug & device makers

$2,348in general payments, 2019–2025

Across 77 payments — averaging $30.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$721
  • Sight Sciences, Inc.$531
  • Novartis$182
  • Iridex Corporation$161
  • Sun Pharmaceutical Industries Inc.$138
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$112
  • plus $504 from 11 others

What the payments were for

  • Food & beverage$2,348100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,348 in reported general payments places this provider in the 60th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois

Medicare billing

Part B allowed, 2024
$199,151
Medicare patients
370
Services billed
2,161

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast33$45,151
ProlensaBromfenac Sodium95$33,623
RhopressaNetarsudil Mesylate43$22,674
BesivanceBesifloxacin Hcl99$22,225
Prednisolone Acetate608$18,736
RestasisCyclosporine20$15,023
SimbrinzaBrinzolamide/Brimonidine Tart59$13,163
RocklatanNetarsudil Mesylat/Latanoprost18$10,681
LumiganBimatoprost16$7,379
Travoprost51$6,194
VyzultaLatanoprostene Bunod11$5,959
Brimonidine Tartrate208$5,065
Cyclosporine11$4,308
Latanoprost423$4,150
Acetazolamide44$3,491

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Besivance$112$55,847194 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$42$33,35661 claims
AbbVieRestasis, Lumigan$15$22,40336 claims
AlconSimbrinza$721$13,16359 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 773 ophthalmology providers in Illinois.

Other ophthalmology in Rockford

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →